Your session is about to expire
← Back to Search
Frozen Plasma + Clotting Factors for Traumatic Hemorrhage (FiiRST-2 Trial)
FiiRST-2 Trial Summary
This trial will help improve care for trauma patients by providing data on the safety and efficacy of two potential treatments for acute trauma coagulopathy.
FiiRST-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.FiiRST-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are older than 16 years.You do not want to receive a blood transfusion for religious or personal reasons.You have had a condition called heparin induced thrombocytopenia (HIT) in the past.You have a severe head injury with a very low score on the Glasgow Coma Scale.You have been using blood thinners in the past 7 days.Showing signs of mental health problems within the first hour of arriving at the hospital's trauma bay or emergency department.Your injury happened more than 3 hours ago.You have received more than 2 units of red blood cells before arriving at the hospital.You have received more than 2 units of red blood cells before the emergency team took special actions.You have a known condition that makes it hard for your blood to clot.People who have had severe injuries from accidents or violence.
- Group 1: Control Group: Standard FP transfusion
- Group 2: Intervention Group- Clotting Factor Concentrates
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has this ever been attempted before?
"Presently, there are 19 concurrent trials for Fibrinogen + PCC being run in 44 urban areas and 13 distinct nations. The first investigation of the drug began in 2018, when PRA Health Sciences ran a Phase 3 study with 200 people's participation to gain approval. Since then, 163 additional tests have been conducted."
Are there any recruitment openings for this experiment?
"Affirmative. Information on clinicaltrials.gov indicates that this trial, which was originally posted April 1st 2021 is currently looking for participants. 350 individuals need to be sourced from 4 distinct centres."
Has the FDA authorized Fibrinogen + PCC for general medical usage?
"Data suggests that Fibrinogen + PCC is approved and thus scores a 3 on our team's safety scale."
What medical cases usually necessitate a prescription of Fibrinogen + PCC?
"Fibrinogen + PCC is the go-to treatment for factor x deficiency and has shown to be effective in preventing perioperative bleeding due to this condition, as well as treating hemorrhage and tissue adhesions."
What is the target number of participants for this clinical trial?
"Affirmative. Clinicaltrials.gov details that this clinical research is currently recruiting participants, having been initially posted on April 1st 2021 and updated as recently as October 4th 2021. 350 patients are needed at four separate sites of study."
Share this study with friends
Copy Link
Messenger